Tony Butler

Jackson Harvey

Matt Biegler

Matthew Biegler

Yun Zhong

Jordyn Fantuzzi

Joseph Catanzaro

Kristen Kluska

Ted Tenthoff

- Marker Therapeutics reported positive Phase 1 clinical results for **MT-601** in relapsed lymphoma from its APOLLO study, demonstrating a **50% complete response rate** and **66% overall response rate** in non-Hodgkin lymphoma patients.  **[1094038_tx_379376_2]** 
- The study highlighted an **excellent safety profile** for MT-601, with **no dose-limiting toxicities** or ICANS, and only mild (Level 1) Cytokine Release Syndrome observed, even at the highest dose of **400 million cells**.  **[1094038_tx_379376_3]** 
- Responses were durable, with **three patients achieving complete response for over a year** and five patients showing clinical benefit for over six months, despite being heavily pretreated, including prior CAR T-cell therapy and bispecifics.  **[1094038_tx_379376_2]** 
- The company plans to proceed with a dose expansion phase for **DLBCL CAR relapse and bispecific relapse patients**, which will form the basis for a future pivotal study, with the goal of seeking accelerated approval.  **[1094038_tx_379376_2]** **[1094038_tx_379376_7]** **[1094038_tx_379376_9]**

Marker Therapeutics Provides Positive Phase 1 Clinical Update for MT-601 in Relapsed Lymphoma

Marker Therapeutics (MRKR)